Labcorp (LH) Stock Forecast & Price Target

Labcorp logo
$367.12 -1.76 (-0.48%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$367.27 +0.15 (+0.04%)
As of 11/20/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Labcorp - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
3
Buy
9

Based on 12 Wall Street analysts who have issued ratings for Labcorp in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 3 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for LH.

Consensus Price Target

$369.08
0.53% Upside
According to the 12 analysts' twelve-month price targets for Labcorp, the average price target is $369.08. The highest price target for LH is $420.00, while the lowest price target for LH is $300.00. The average price target represents a forecasted upside of 0.53% from the current price of $367.12.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for LH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Labcorp and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LH Analyst Ratings Over Time

TypeCurrent Forecast
11/22/25 to 11/22/26
1 Month Ago
10/23/25 to 10/23/26
3 Months Ago
8/24/25 to 8/24/26
1 Year Ago
11/22/24 to 11/22/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
9 Buy rating(s)
12 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$369.08$337.73$330.00$297.07
Forecasted Upside0.53% Upside2.62% Upside-2.76% Downside11.76% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

LH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Labcorp Stock vs. The Competition

TypeLabcorpHealthcare CompaniesBroader Market
Consensus Rating Score
2.83
2.32
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside0.53% Upside121.33% Upside22.05% Upside
News Sentiment Rating
Neutral News

See Recent LH News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/5/2026
HSBC Holdings plc logo
HSBC
2 of 5 stars
 UpgradeHold ➝ Buy$410.00+11.40%
10/29/2026
Deutsche Bank logo
Deutsche Bank
3 of 5 stars
 Reiterated RatingHold$355.00-2.06%
10/29/2026
UBS Group AG logo
UBS Group
4 of 5 stars
Kevin Caliendo
Kevin Caliendo
4 of 5 stars
Boost TargetBuy$380.00 ➝ $420.00+16.28%
10/29/2026Reiterated RatingOverweight$388.00+7.42%
10/29/2026Boost TargetBuy$365.00 ➝ $395.00+9.04%
10/29/2026Boost TargetOutperform$361.00 ➝ $396.00+9.94%
10/28/2026Boost TargetEqual Weight$330.00 ➝ $380.00+4.97%
10/28/2026Set Target$410.00+13.25%
10/21/2026 UpgradeBuy (B+) ➝ Buy (A-)
8/10/2026Set Target$355.00+11.16%
8/4/2026Boost TargetNeutral$300.00 ➝ $309.00+1.00%
8/3/2026Boost TargetOverweight$330.00 ➝ $360.00+16.31%
7/13/2026Boost TargetBuy$300.00 ➝ $320.00+14.89%
4/8/2026 Reiterated RatingOutperform$300.00+14.07%
4/2/2025Initiated CoverageBuy$276.00+18.64%
3/4/2025UpgradeNeutral ➝ Buy$250.00 ➝ $300.00+18.11%
2/6/2025Boost TargetBuy$275.00 ➝ $290.00+17.25%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:48 AM ET.


Should I Buy Labcorp Stock? LH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, November 21, 2026. Please send any questions or comments about these Labcorp pros and cons to contact@marketbeat.com.

Labcorp
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

  • Wall Street sentiment has turned sharply positive, with the consensus price target rising to $369.08, which is slightly above the current stock price of $367.12, suggesting the market may be undervaluing the stock relative to analyst expectations. This is reinforced by a recent upgrade from Wall Street Zen to a "Strong-Buy" rating and a "Moderate Buy" consensus from twelve research firms, indicating strong institutional confidence in the company's future performance.
  • The company demonstrated strong fundamental performance in its most recent quarter, reporting earnings per share of $4.78, which beat the consensus estimate of $4.64 by $0.14. Revenue also exceeded expectations at $3.81 billion, up 6.9% year-over-year, showing that the company is successfully growing its top line while maintaining profitability with a net margin of 6.88%.
  • Management has provided robust forward-looking guidance for fiscal year 2026, projecting earnings per share between $18.10 and $18.55, which is at the higher end of the consensus estimate of $18.34. This guidance, combined with a revenue outlook of $14.7 billion to $14.8 billion, suggests that the company expects to maintain its growth trajectory and deliver strong results for shareholders in the coming year.
  • Short interest in the stock has been declining, with the number of shares shorted dropping to 2,544,414 in the most recent reporting period, a decrease from 2,557,656 in the previous month. This reduction in short positions, along with a low short percentage of float at 3.16%, indicates that fewer investors are betting against the stock, which can be a bullish signal for future price appreciation.
  • The company is expanding its clinical trial operations in Brazil through a collaboration with Grupo Fleury, which will bring clinical trial services closer to research sites and patients. This strategic move supports global studies and positions Laboratory Co. of America Holdings to capture more revenue from the growing pharmaceutical and biotechnology sectors, which are key drivers of its business.

Labcorp
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Laboratory Co. of America Holdings for these reasons:

  • Management has warned of a potential $125 million risk related to a reduction in government reimbursement rates in 2027, which could negatively impact the company's profitability. This risk is particularly concerning given that the company's central laboratory business and diagnostic testing are major drivers of its growth, and any changes in Medicare fee schedules could erode margins and reduce earnings.
  • Insider selling has been consistent, with executives such as EVP Amy Summy and EVP Brian Caveney selling shares in November 2026 at prices above $370. While insider sales can be due to personal financial reasons, the frequency and size of these transactions, including a 5.47% decrease in Caveney's position, may signal that company insiders are less confident in the stock's near-term upside or are taking advantage of the recent price run-up.
  • The stock is trading near its 52-week high of $375.10, with the current price of $367.12 only 2.1% below that level. This proximity to the high suggests that the stock may be overextended in the short term, and any negative news or market volatility could lead to a significant pullback, especially given that the 50-day moving average is $334.72, indicating a steep recent rally that may not be sustainable.
  • Some institutional investors have reduced their positions in the company, such as Boston Partners, which decreased its stake by 3.4% in the third quarter. While other institutions have increased their holdings, the mixed signals from major investors, including some trimming their positions, could indicate uncertainty about the company's long-term growth prospects or valuation.

LH Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Labcorp is $369.08, with a high forecast of $420.00 and a low forecast of $300.00.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Labcorp in the last year. There are currently 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LH shares.

According to analysts, Labcorp's stock has a predicted upside of 0.53% based on their 12-month stock forecasts.

Over the previous 90 days, Labcorp's stock had 3 upgrades by analysts.

Labcorp has been rated by research analysts at Barclays, Deutsche Bank, HSBC, Leerink Partners, Morgan Stanley, Robert W. Baird, Truist Financial, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Labcorp more than other "healthcare" companies. The consensus rating for Labcorp is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how LH compares to other companies.


MarketBeat monitors more than a dozen sources for Labcorp analyst ratings, with the most recent rating issued on 11/5/2026.
From Our Partners